Bronchiolitis obliterans postallogeneic stem cell transplantation: What is new?;Bronchiolite oblitérante après allogreffe de cellules souches hématopoïétiques: quels progrès?

Revue de Pneumologie Clinique

Volumn 67, Issue 4, 2011, Pages 258-266

  Lemonnier, F ^a,b   Dhedin, N ^b   Catherinot, E ^a   Tcherakian, C ^a   Neveu, H ^a   Suarez, F ^c   Becquemin, M H ^b   Devillier, P ^d,e   Vernant, J P ^b   Couderc, L J ^a,d,e   Rivaud, E ^a  

^a FOCH HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^e UPRES EA 220   (France)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Azythromycin; Imatinib; Lung transplantation; Obstructive bronchiolitis

Indexed keywords

AZITHROMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LEUKOCYTE ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; STEROID;

ALLOGENEIC STEM CELL TRANSPLANTATION; BRONCHIOLITIS OBLITERANS; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; HUMAN; IMMUNOTHERAPY; LUNG TRANSPLANTATION; MORBIDITY; PATHOPHYSIOLOGY; PHOTOCHEMOTHERAPY; REVIEW;

BRONCHIOLITIS OBLITERANS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; RISK FACTORS;

EID: 80052714526     PISSN: 07618417     EISSN: 17762561     Source Type: Journal    
DOI: 10.1016/j.pneumo.2011.06.003     Document Type: Review

References (92)

1. Copelan E.A. Hematopoietic stem-cell transplantation. N Engl J Med 2006, 354:1813-1826.
2. Peffault de Latour R., Cabrespine-Faugeras A., Bay J.O. Ten years of changes in conditioning regimen for allogenic hematopoietic stem cell transplantation in adults. Bull Cancer 2008, 95:87-97.
3. Lim do H., Lee J., Lee H.G., Park B.B., Peck K.R., Oh W.S., et al. Pulmonary complications after hematopoietic stem cell transplantation. J Korean Med Sci 2006, 21:406-411.
4. Palmas A., Tefferi A., Myers J.L., Scott J.P., Swensen S.J., Chen M.G., et al. Late-onset non-infectious pulmonary complications after allogeneic bone marrow transplantation. Br J Haematol 1998, 100:680-687.
5. Sharma S., Nadrous H.F., Peters S.G., Tefferi A., Litzow M.R., Aubry M.C., et al. Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings. Chest 2005, 128:1385-1392.
6. Williams K.M., Chien J.W., Gladwin M.T., Pavletic S.Z. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA 2009, 302:306-314.
7. Dudek A.Z., Mahaseth H., DeFor T.E., Weisdorf D.J. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant 2003, 9:657-666.
8. Chien J.W., Martin P.J., Gooley T.A., Flowers M.E., Heckbert S.R., Nichols W.G., et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2003, 168:208-214.
9. Soubani A.O., Uberti J.P. Bronchiolitis obliterans following haematopoietic stem cell transplantation. Eur Respir J 2007, 29:1007-1019.
10. Yousem S.A. The histological spectrum of pulmonary graft-versus-host disease in bone marrow transplant recipients. Hum Pathol 1995, 26:668-675.
11. Erard V., Chien J.W., Kim H.W., Nichols W.G., Flowers M.E., Martin P.J., et al. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. J Infect Dis 2006, 193:1619-1625.
12. Santo Tomas L.H., Loberiza F.R., Klein J.P., Layde P.M., Lipchik R.J., Rizzo J.D., et al. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. Chest 2005, 128:153-161.
13. Ringden O., Remberger M., Ruutu T., Nikoskelainen J., Volin L., Vindelov L., et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood 1999, 93:2196-2201.
14. Yoshihara S., Tateishi U., Ando T., Kunitoh H., Suyama H., Onishi Y., et al. Lower incidence of bronchiolitis obliterans in allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning compared with myeloablative conditioning. Bone Marrow Transplant 2005, 35:1195-1200.
15. Nusair S., Breuer R., Shapira M.Y., Berkman N., Or R. Low incidence of pulmonary complications following non-myeloablative stem cell transplantation. Eur Respir J 2004, 23:440-445.
16. Philit F., Wiesendanger T., Archimbaud E., Mornex J.F., Brune J., Cordier J.F. Post-transplant obstructive lung disease (" bronchiolitis obliterans" ): a clinical comparative study of bone marrow and lung transplant patients. Eur Respir J 1995, 8:551-558.
17. Stewart S., Fishbein M.C., Snell G.I., Berry G.J., Boehler A., Burke M.M., et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007, 26:1229-1242.
18. Yousem S.A., Berry G.J., Cagle P.T., Chamberlain D., Husain A.N., Hruban R.H., et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 1996, 15:1-15.
19. Vanaudenaerde B.M., Meyts I., Vos R., Geudens N., De Wever W., Verbeken E.K., et al. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J 2008, 32:832-843.
20. Nakagiri T., Inoue M., Morii E., Minami M., Sawabata N., Utsumi T., et al. Local IL-17 production and a decrease in peripheral blood regulatory T cells in an animal model of bronchiolitis obliterans. Transplantation 2010, 89:1312-1319.
21. Vanaudenaerde B.M., De Vleeschauwer S.I., Vos R., Meyts I., Bullens D.M., Reynders V., et al. The role of the IL23/IL17 axis in bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant 2008, 8:1911-1920.
22. Sato M., Keshavjee S. Bronchiolitis obliterans syndrome: alloimmune-dependent and -independent injury with aberrant tissue remodeling. Semin Thorac Cardiovasc Surg 2008, 20:173-182.
23. Shilling R.A., Wilkes D.S. Immunobiology of chronic lung allograft dysfunction: new insights from the bench and beyond. Am J Transplant 2009, 9:1714-1718.
24. Hadjiliadis D., Duane Davis R., Steele M.P., Messier R.H., Lau C.L., Eubanks S.S., et al. Gastroesophageal reflux disease in lung transplant recipients. Clin Transplant 2003, 17:363-368.
25. Davis R.D., Lau C.L., Eubanks S., Messier R.H., Hadjiliadis D., Steele M.P., et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardiovasc Surg 2003, 125:533-542.
26. Young L.R., Hadjiliadis D., Davis R.D., Palmer S.M. Lung transplantation exacerbates gastroesophageal reflux disease. Chest 2003, 124:1689-1693.
27. D'Ovidio F., Keshavjee S. Gastroesophageal reflux and lung transplantation. Dis Esophagus 2006, 19:315-320.
28. Botha P., Archer L., Anderson R.L., Lordan J., Dark J.H., Corris P.A., et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation 2008, 85:771-774.
29. Soubani A.O., Pandya C.M. The spectrum of non-infectious pulmonary complications following hematopoietic stem cell transplantation. Hematol Oncol Stem Cell Ther 2010, 3:143-157.
30. Clark J.G., Crawford S.W., Madtes D.K., Sullivan K.M. Obstructive lung disease after allogeneic marrow transplantation. Clinical presentation and course. Ann Intern Med 1989, 111:368-376.
31. Ueda K., Watadani T., Maeda E., Ota S., Kataoka K., Seo S., et al. Outcome and treatment of late-onset noninfectious pulmonary complications after allogeneic haematopoietic SCT. Bone Marrow Transplant 2010, 45:1719-1727.
32. Guihot A., Becquemin M.H., Couderc L.J., Randrianarivelo O., Rivaud E., Philippe B., et al. Telemetric monitoring of pulmonary function after allogeneic hematopoietic stem cell transplantation. Transplantation 2007, 83:554-560.
33. Fraser C.J., Scott Baker K. The management and outcome of chronic graft-versus-host disease. Br J Haematol 2007, 138:131-145.
34. Afessa B., Litzow M.R., Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant 2001, 28:425-434.
35. Ratjen F., Rjabko O., Kremens B. High-dose corticosteroid therapy for bronchiolitis obliterans after bone marrow transplantation in children. Bone Marrow Transplant 2005, 36:135-138.
36. Payne L., Chan C.K., Fyles G., Hyland R.H., Bafundi P., Yeung M., et al. Cyclosporine as possible prophylaxis for obstructive airways disease after allogeneic bone marrow transplantation. Chest 1993, 104:114-118.
37. Sanchez J., Torres A., Serrano J., Roman J., Martin C., Perula L., et al. Long-term follow-up of immunosuppressive treatment for obstructive airways disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997, 20:403-408.
38. Sakaida E., Nakaseko C., Harima A., Yokota A., Cho R., Saito Y., et al. Late-onset non-infectious pulmonary complications after allogeneic stem cell transplantation are significantly associated with chronic graft-versus-host disease and with the graft-versus-leukemia effect. Blood 2003, 102:4236-4242.
39. Busca A., Locatelli F., Marmont F., Audisio E., Falda M. Response to mycophenolate mofetil therapy in refractory chronic graft-versus-host disease. Haematologica 2003, 88:837-839.
40. Ghez D., Rubio M.T., Maillard N., Suarez F., Chandesris M.O., Delarue R., et al. Rapamycin for refractory acute graft-versus-host disease. Transplantation 2009, 88:1081-1087.
41. Hernandez R.L., Gil P.U., Gallo C.G., de Pablo Gafas A., Hernandez M.C., Alvarez M.J. Rapamycin in lung transplantation. Transplant Proc 2005, 37:3999-4000.
42. Azzola A., Havryk A., Chhajed P., Hostettler K., Black J., Johnson P., et al. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation 2004, 77:275-280.
43. Perosa F., Prete M., Racanelli V., Dammacco F. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic. J Intern Med 2010, 267:260-277.
44. Kharfan-Dabaja M.A., Mhaskar A.R., Djulbegovic B., Cutler C., Mohty M., Kumar A. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transplant 2009, 15:1005-1013.
45. McIver Z., Stephens N., Grim A., Barrett A.J. Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias. Biol Blood Marrow Transplant 2010, 16:1549-1556.
46. Sano H., Kikuta A., Ito M., Nemoto K., Hojo H., Ohto H. Successful treatment with combined anti-thymocyte globulin and methylprednisolone for bronchiolitis obliterans after allogeneic bone marrow transplantation in a child with chronic myelogenous leukemia. Rinsho Ketsueki 2002, 43:23-28.
47. Fullmer J.J., Fan L.L., Dishop M.K., Rodgers C., Krance R. Successful treatment of bronchiolitis obliterans in a bone marrow transplant patient with tumor necrosis factor-alpha blockade. Pediatrics 2005, 116:767-770.
48. Alho H.S., Maasilta P.K., Harjula A.L., Hammainen P., Salminen J., Salminen U.S. Tumor necrosis factor-alpha in a porcine bronchial model of obliterative bronchiolitis. Transplantation 2003, 76:516-523.
49. Ding I.B., Baumgartner R.A., Schwaiblmair M., Behr J. Administration of anti-interleukin-2Ralpha monoclonal antibody in bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2003, 75:1767-1769.
50. Peritt D. Potential mechanisms of photopheresis in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006, 12:7-12.
51. Pothiawala S.Z., Baldwin B.T., Cherpelis B.S., Lien M.H., Fenske N.A. The role of phototherapy in cutaneous T-cell lymphoma. J Drugs Dermatol 2010, 9:764-772.
52. Mayes M.D. Photopheresis and autoimmune diseases. Rheum Dis Clin North Am 2000, 26:75-81. [viii-ix].
53. Ilhan O., Arat M., Arslan O., Ayyildiz E., Sanli H., Beksac M., et al. Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease. Transfus Apher Sci 2004, 30:185-187.
54. Couriel D.R., Hosing C., Saliba R., Shpall E.J., Anderlini P., Rhodes B., et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 2006, 107:3074-3080.
55. Tikkanen J.M., Hollmen M., Nykanen A.I., Wood J., Koskinen P.K., Lemstrom K.B. Role of platelet-derived growth factor and vascular endothelial growth factor in obliterative airway disease. Am J Respir Crit Care Med 2006, 174:1145-1152.
56. Olivieri A., Locatelli F., Zecca M., Sanna A., Cimminiello M., Raimondi R., et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood 2009, 114:709-718.
57. Stadler M., Ahlborn R., Kamal H., Diedrich H., Buchholz S., Eder M., et al. Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease. Blood 2009, 114:3718-3719. [author reply 3719-20].
58. Parker P.M., Chao N., Nademanee A., O'Donnell M.R., Schmidt G.M., Snyder D.S., et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995, 86:3604-3609.
59. Browne P.V., Weisdorf D.J., DeFor T., Miller W.J., Davies S.M., Filipovich A., et al. Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplant 2000, 26:865-869.
60. Culic O., Erakovic V., Parnham M.J. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001, 429:209-229.
61. Maimon N., Lipton J.H., Chan C.K., Marras T.K. Macrolides in the treatment of bronchiolitis obliterans in allograft recipients. Bone Marrow Transplant 2009, 44:69-73.
62. Southern K.W., Barker P.M. Azithromycin for cystic fibrosis. Eur Respir J 2004, 24:834-838.
63. Poletti V., Casoni G., Chilosi M., Zompatori M. Diffuse panbronchiolitis. Eur Respir J 2006, 28:862-871.
64. Gerhardt S.G., McDyer J.F., Girgis R.E., Conte J.V., Yang S.C., Orens J.B. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med 2003, 168:121-125.
65. Verleden G.M., Dupont L.J. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2004, 77:1465-1467.
66. Yates B., Murphy D.M., Forrest I.A., Ward C., Rutherford R.M., Fisher A.J., et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2005, 172:772-775.
67. Shitrit D., Bendayan D., Gidon S., Saute M., Bakal I., Kramer M.R. Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant 2005, 24:1440-1443.
68. Vanaudenaerde B.M., Wuyts W.A., Geudens N., Dupont L.J., Schoofs K., Smeets S., et al. Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells. Am J Transplant 2007, 7:76-82.
69. Sassa K., Mizushima Y., Fujishita T., Oosaki R., Kobayashi M. Therapeutic effect of clarithromycin on a transplanted tumor in rats. Antimicrob Agents Chemother 1999, 43:67-72.
70. Murphy D.M., Forrest I.A., Ward C., Corris P.A., Johnson G.E., Jones D., et al. Effect of azithromycin on primary bronchial epithelial cells derived from stable lung allografts. Thorax 2007, 62:834.
71. Kanai K., Asano K., Hisamitsu T., Suzaki H. Suppression of matrix metalloproteinase-9 production from neutrophils by a macrolide antibiotic, roxithromycin, in vitro. Mediators Inflamm 2004, 13:313-319.
72. Sifrim D., Matsuo H., Janssens J., Vantrappen G. Comparison of the effects of midecamycin acetate and azithromycin on gastrointestinal motility in man. Drugs Exp Clin Res 1994, 20:121-126.
73. Westphal J.F. Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 2000, 50:285-295.
74. Khalid Y., Mellgren K., Fasth A., Lindblad A., Gustafsson P. Obliterative bronchiolitis after stem cell transplantation. Inert gas washout makes early diagnosis of this serious complication possible. Lakartidningen 2007, 104:3373-3376.
75. Saiman L., Anstead M., Mayer-Hamblett N., Lands L.C., Kloster M., Hocevar-Trnka J., et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with pseudomonas aeruginosa: a randomized controlled trial. JAMA 2010, 303:1707-1715.
76. Bashoura L., Gupta S., Jain A., Couriel D.R., Komanduri K.V., Eapen G.A., et al. Inhaled corticosteroids stabilize constrictive bronchiolitis after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008, 41:63-67.
77. Bergeron A., Belle A., Chevret S., Ribaud P., Devergie A., Esperou H., et al. Combined inhaled steroids and bronchodilatators in obstructive airway disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2007, 39:547-553.
78. Or R., Gesundheit B., Resnick I., Bitan M., Avraham A., Avgil M., et al. Sparing effect by montelukast treatment for chronic graft versus host disease: a pilot study. Transplantation 2007, 83:577-581.
79. K. Williams SP, O. Hnatiuk, F. Hakim, S. Mitchell, J. Gea-Banacloche, L. Comis, et al. Preliminary results of a phase II trial of montelukast for the treatment of bronchiolitis obliterans syndrome after HSCT. Vienna: EBMT; 2010 Report No.: O255.
80. Hori A., Kanda Y., Goyama S., Onishi Y., Komeno Y., Mitani K., et al. A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease. Transplantation 2005, 79:372-374.
81. Shimabukuro-Vornhagen A., Liebig T., von Bergwelt-Baildon M. Statins inhibit human APC function: implications for the treatment of GVHD. Blood 2008, 112:1544-1545.
82. Rotta M., Storer B.E., Storb R., Martin P.J., Flowers M.E., Vernon M.S., et al. Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010, 16:1463-1466.
83. Rotta M., Storer B.E., Storb R.F., Martin P.J., Heimfeld S., Peffer A., et al. Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation. Blood 2010, 115:1288-1295.
84. Murphy D.M., Forrest I.A., Corris P.A., Johnson G.E., Small T., Jones D., et al. Simvastatin attenuates release of neutrophilic and remodeling factors from primary bronchial epithelial cells derived from stable lung transplant recipients. Am J Physiol Lung Cell Mol Physiol 2008, 294:L5592.
85. Johnson B.A., Iacono A.T., Zeevi A., McCurry K.R., Duncan S.R. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med 2003, 167:1271-1278.
86. Duncan C.N., Barry E.V., Lehmann L.E. Tolerability of pravastatin in pediatric hematopoietic stem cell transplant patients with bronchiolitis obliterans. J Pediatr Hematol Oncol 2010, 32:185-188.
87. Tichelli A, Rovo A, Gratwohl A. Late pulmonary, cardiovascular, and renal complications after hematopoietic stem cell transplantation and recommended screening practices. Hematology Am Soc Hematol Educ Program 2008:125-33.
88. Calhoon J.H., Levine S., Anzueto A., Bryan C.L., Trinkle J.K. Lung transplantation in a patient with a prior bone marrow transplant. Chest 1992, 102:948.
89. Heath J.A., Kurland G., Spray T.L., Kernan N.A., Small T.N., Brochstein J.A., et al. Lung transplantation after allogeneic marrow transplantation in pediatric patients: the Memorial Sloan-Kettering experience. Transplantation 2001, 72:1986-1990.
90. Boas S.R., Noyes B.E., Kurland G., Armitage J., Orenstein D. Pediatric lung transplantation for graft-versus-host disease following bone marrow transplantation. Chest 1994, 105:1584-1586.
91. Matsuzaki A., Suminoe A., Koga Y., Hara T., Shiraishi T. Lung transplantation after hematopoietic stem cell transplantation from the same living donor in a child with juvenile myelomonocytic leukemia and bronchiolitis obliterans. Pediatr Blood Cancer 2008, 51:567.
92. Yamane M., Sano Y., Toyooka S., Okazaki M., Date H., Oto T. Living-donor lobar lung transplantation for pulmonary complications after hematopoietic stem cell transplantation. Transplantation 2008, 86:1767-1770.